The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

Neon Hospital

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: Subconjunctival bevacizumab (Altuzan)

Study type: Interventional

Funder types: Other

Identifiers

NCT02796183

2015-1

Details and patient eligibility

About

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

Full description

At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.

Enrollment: 20 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having diffuse diabetic macular edema persisted at least 1 month
• No intravitreal injection in last 3 months.
• No retinal laser photocoagulation in last 6 months
• Not have any other macular disease causing macular edema

Exclusion criteria

• Having ischemic macula
• Intravitreal injection in last 3 months.
• Retinal laser photocoagulation in last 6 months
• Have any other macular disease causing macular edema

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Diabetic macular edema

Other group

Description:

Bevacizumab (Altuzan) was injected subconjunctival space of the patients.

Treatment:

Drug: Subconjunctival bevacizumab (Altuzan)